The efficacy of Adenoprosin® in combined treatment of patients with chronic bacterial prostatitis

Background. Chronic bacterial prostatitis is a common disease clinically diagnosed based on signs of inflammation and the presence of infection in the prostatic fluid. Standard antibiotic therapy in most cases does not lead to a decrease in the number of recurrences. In this regard, an integrated approach is often used in therapy, and in addition to antibacterial therapy, biostimulators, extracts of various plants and animals are prescribed. One of the main advantages of these prescriptions is that the drugs have minimal side effects.

Objective. To assess the effectiveness of Adenoprosin® in the combined treatment of patients with chronic bacterial prostatitis.

Material and Methods. 60 patients aged 24–50 (average age is 31.3 ± 2.8 years) with chronic bacterial prostatitis were examined and treated, the duration of the disease ranged from 6 months to 15 years (average duration of the disease is 1.5 ± 0.3 years). The patients were divided into two groups: group I included 30 patients who were treated with antibacterial drugs and Adenoprosin®, group II included 30 patients who were treated with antibacterial drugs only. The course of treatment lasted 30 days, the total time of observation of the patients was 3 months. Clinical control was carried out during the first visit to the urologist, on the 14th, 28th, 45th and 90th days from the start of therapy and included filling out the following: The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), The International Prostate Symptom Score (IPSS) and Quality of Life (QoL), as well as the International Index of Erectile Function (IIEF-5) questionnaire in order to identify the possible effect of therapy on sexual function.

Results. The analysis revealed that the use of the Adenoprosin® in complex therapy in patients with chronic bacterial prostatitis reduces the overall score of the NIH-CPSI questionnaire by an average of 4 points. When conducting a questionnaire at the end of treatment, 2 (6.6%) patients in the group II noted dissatisfaction with the therapy, on the 90th day of observation, complaints of dissatisfaction with the treatment remained in 1 (3.3%) patient. In 5 (16.6%) patients of the group II, against the background of the therapy, there was no subjective improvement in the treatment; on the 90th day of observation, the number of unsatisfied patients remained the same. Microscopic examination of the prostatic fluid and microflora after 28-day-treatment showed the decrease in leukocytes (less than 10 leukocytes in the field of view) in 25 (80%) patients of the group I. This point was higher in comparison with 21 (70%) patients of the group II. In 5 (16.6%) patients of the group I, the number of leukocytes in the prostatic fluid was in the range of 10–20 in the field of view, all patients previously had recurrent forms of the disease. The number of leukocytes more than 10 was in 7 (23.3%) patients of the group II after antibacterial therapy. Among them, 5 (16.6%) patients had recurrent forms of the disease, and 2 (6.6%) patients were diagnosed with prostatitis for the first time. Thus, the use of combination therapy in the group I, to a greater extent, reduced the inflammatory markers of the disease.

Conclusion. The Adenoprosin® in complex therapy has a proven anti-inflammatory effect on the prostate gland, reduces the pain rapidly, decreases the total score of prostatic symptoms when analyzing the NIH-CPSI questionnaires, improves erectile function, reduces markers of inflammation in the pre-fetal gland and can be recommended for patients with chronic bacterial inflammation in the prostate gland.

1. European Association of Urologists Guidelines. Moscow, 2019. 300 p. (In Russ.).

2. Alyaev YuG, Glybochko PV, Pushkar DYu (eds). Urology. Russian Clinical Guidelines. Moscow: GEOTAR-Media; 2018. 480 p. (In Russ.).

3. Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116:509–25. PMID: 25711488. PMCID: PMC5008168. doi:10.1111/bju.13101

4. Apolikhin OI, Komarova VA, Nikushina AA, Sivkov AV. Prostate diseases in the Russian Federation: statistical data for 2008–2017. Experimental and Clinical Urology. 2019;2:4–13. (In Russ.). doi:10.29188/2222-8543-2019-11-2-4-12

5. Polackwich AS, Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer Prostatic Dis. 2016;19:132–8. PMID: 26951713. doi:10.1038/pcan.2016.8

6. Krupin VN, Belova AN, Krupin AV. Treatment of patients with chronic bacterial prostatitis. Urology Herald. 2019;7(1):26–37. (In Russ.). doi:10.21886/2308-6424-2019-7-1-26-37

7. Kogan MI, Naboka J, Gudima I, Ibishev H. Prostatic secretion microbiota and chronic bacterial prostatitis symptoms or sings: is there a connection? Eur Urol Suppl. 2017;16(3):e145. doi:10.1016/S1569-9056(17)30152-5

8. Ibishev KS, Kogan MI, Krainiy PA, et al. Comparative analysis of clinical and laboratory parameters in patients with chronic primary bacterial prostatitis and chronic recurrent bacterial prostatitis. Eur Urol Suppl. 2019;18(2):e2330. doi:10.1016/S1569-9056(19)32033-0

9. Kogan MI, Naboka YuL, Ismailov RS. Microbiota of prostate secretion: comparative analysis of chronic prostatitis categories II and IIIA. Urologiia = Urology. 2020;2:16–22. (In Russ.). doi:10.18565/urology.2020.2

10. Karpov EI. Modern view on the treatment of the lower urinary tract syndrome: cytomedines as a class of drugs. Russian Medical Journal. 2017;25(27):1992–6. (In Russ.).

11. Official package insert for the Adenoprosin®. (In Russ.).

12. Dumbraveanu I, Banov P, Arian I, Tanase A. The use of entomological drugs in complex treatment of patients with chronic prostatitis and erectile dysfunction. Moldovan Journal of Health Sciences. 2017;14(4):31-43. (In Engl. and Mold.).